Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic VulnerabilityGlobeNewsWire · 19 hr ago
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansGlobeNewsWire · 4 days ago
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansGlobeNewsWire · 4 days ago
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer CellsGlobeNewsWire · Oct 16, 2026
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian CancerGlobeNewsWire · Oct 14, 2026
Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Increase in Short InterestDefense World · Oct 13, 2026Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer.